The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Endocrine Disorder in Patients With Craniopharyngioma
Abstract
Craniopharyngioma is an intracranial congenital epithelial tumor growing along the pathway of the embryonic craniopharyngeal tube. The main clinical symptoms of patients with craniopharyngioma include high intracranial pressure, visual field defect, endocrine dysfunction, and hypothalamic dysfunction. At present, the preferred treatment remains the surgical treatment, but the recovery of endocrine and hypothalamic function following surgery is limited. In addition, endocrine disorders often emerge following surgery, which seriously reduces the quality of life of patients after operation. So far, research on craniopharyngioma focuses on ways to ameliorate endocrine dysfunction. This article reviews the latest research progress on pathogenesis, manifestation, significance, and treatment of endocrine disorders in patients with craniopharyngioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the case of frequently encountered tumor- and/or treatment-associated adrenocorticotropin deficiency in CP patients, hydrocortisone-substitution therapy and flexible-dose adaptation with regard to stress situations are mandatory (168, 171).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [171]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
Gravholt, C. H., Andersen, N. H., Conway, G. S., Dekkers, O. M., Geffner, M. E., Klein, K. O., Lin, A. E., Mauras, N., Quigley, C. A., Rubin, K., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0430 · Cited by 1,101
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up
Karavitaki, N., Brufani, C., Warner, J. T., Adams, C. B. T., Richards, P., Ansorge, O., Shine, B., Turner, H. E., & Wass, J. A. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02231.x · Cited by 633
Ho, K. K. Y., & _, _. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0631 · Cited by 615
Kupelian, V., Page, S. T., Araujo, A. B., Travison, T. G., Bremner, W. J., & McKinlay, J. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1326 · Cited by 561
Karavitaki, N., Cudlip, S., Adams, C. B. T., & Wass, J. A. H. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0002 · Cited by 514
Brambilla, D. J., Matsumoto, A. M., Araujo, A. B., & McKinlay, J. B. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1902 · Cited by 448 · cited 1×
“Diagnostic criteria for hypopituitarism: (1) gonadal axis dysfunction: testosterone (TEST) decreased with abnormal follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin (PRL) levels in adult male patients, estradiol (E2) decreased with normal or decreased FSH and LH or abnormal PRL in female pati…”
Background
Research works printed but not linked: 112
- Fernandez-Miranda, 2012, Craniopharyngioma: a pathologic, clinical, and surgical review, Head Neck., 34, 1036, 10.1002/hed.21771 · DOI · Paper page
- Huang, 2021, Clinical and endocrinological manifestations of childhood-onset craniopharyngioma before surgical removal: a report from one medical center in Taiwan, Pediatr Neonatol., 62, 181, 10.1016/j.pedneo.2020.08.014 · DOI
- DeVile, 1996, Growth and endocrine sequelae of craniopharyngioma, Arch Dis Child., 75, 108, 10.1136/adc.75.2.108 · DOI · Paper page
- Jazbinsek, 2020, Prevalence of endocrine and metabolic comorbidities in a national cohort of patients with craniopharyngioma, Horm Res Paediatr., 93, 46, 10.1159/000507702 · DOI
- Wijnen, 2018, The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up, Eur J Endocrinol., 178, 11, 10.1530/EJE-17-0387 · DOI
- Hussein, 2020, Temporal trends in craniopharyngioma management and long-term endocrine outcomes: A multicentre cross-sectional study, Clin Endocrinol., 94, 242, 10.1111/cen.14334 · DOI
- Qi, 2018, [Hypopituitarism mode in patients with craniopharyngioma in relation to tumor growth pattern], Zhonghua yi xue za zhi., 98, 19
- Rostami, 2017, Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy, Acta Neurochir., 159, 2217, 10.1007/s00701-017-3311-0 · DOI
- Mende, 2020, Clinical situation, therapy, and follow-up of adult craniopharyngioma, J Clin Endocrinol Metab., 105, 43, 10.1210/clinem/dgz043 · DOI
- Wijnen, 2017, Very long-term sequelae of craniopharyngioma, Eur J Endocrinol., 176, 755, 10.1530/EJE-17-0044 · DOI
- Sterkenburg, 2015, Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes, Neuro Oncol., 17, 1029, 10.1093/neuonc/nov044 · DOI · Paper page
- Pascual, 2018, Cystic tumors of the pituitary infundibulum: seminal autopsy specimens (1899 to 1904) that allowed clinical-pathological craniopharyngioma characterization, Pituitary., 21, 393, 10.1007/s11102-018-0889-z · doi:10.1007/s11102-018-0889-z
- Guo, 2019, Comparative evaluation of neuroendocrine dysfunction in children with craniopharyngiomas before and after mass effects are removed, J Pediatr Endocrinol Metab., 32, 127, 10.1515/jpem-2018-0204 · doi:10.1515/jpem-2018-0204
- Pan, 2016, Growth patterns of craniopharyngiomas: clinical analysis of 226 patients, J Neurosurg Pediatr., 17, 418, 10.3171/2015.7.PEDS14449 · DOI
- Liu, 2018, Pathological relationship between adamantinomatous craniopharyngioma and adjacent structures based on QST classification, J Neuropathol Exp Neurol., 77, 1017, 10.1093/jnen/nly083 · doi:10.1093/jnen/nly083
- Almistehi, 2020, Secondary pituitary hormonal dysfunction patterns: tumor size and subtype matter, Pituitary., 23, 622, 10.1007/s11102-020-01067-7 · DOI
- Olsson, 2015, Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden, J Clin Endocrinol Metab., 100, 467, 10.1210/jc.2014-3525 · DOI · Paper page
- Bao, 2016, Origin of craniopharyngiomas: implications for growth pattern, clinical characteristics, and outcomes of tumor recurrence, J Neurosurg., 125, 24, 10.3171/2015.6.JNS141883 · DOI
- DiPatri, 2005, history of the treatment of craniopharyngiomas, ChNS., 21, 606, 10.1007/s00381-005-1224-3 · doi:10.1007/s00381-005-1224-3
- Hoffman, 1992, Aggressive surgical management of craniopharyngiomas in children, J Neurosurg., 76, 47, 10.3171/jns.1992.76.1.0047 · DOI · Paper page
- Meuric, 2005, Influence of tumor location on the presentation and evolution of craniopharyngiomas, J Neurosurg., 103, 421, 10.3171/ped.2005.103.5.0421 · DOI
- Prieto, 2016, Craniopharyngioma adherence: a comprehensive topographical categorization and outcome-related risk stratification model based on the methodical examination of 500 tumors, Neurosurg Focus., 41, E13, 10.3171/2016.9.FOCUS16304 · DOI
- Honegger, 2008, Craniopharyngioma surgery, Pituitary., 11, 361, 10.1007/s11102-008-0137-z · DOI
- Cheng, 2017, Effect of preserving the pituitary stalk during resection of craniopharyngioma in children on the diabetes insipidus and relapse rates and long-term outcomes, J Craniofac Surg., 28, e591, 10.1097/SCS.0000000000003920 · DOI
- Ocal, 2008, Permanent central diabetes insipidus with complete regression of pituitary stalk enlargement after 4 years of follow-up, J Clin Res Pediatr Endocrinol., 1, 38, 10.4008/jcrpe.v1i1.4 · doi:10.4008/jcrpe.v1i1.4
- Schreckinger, 2013, Post-operative diabetes insipidus after endoscopic transsphenoidal surgery, Pituitary., 16, 445, 10.1007/s11102-012-0453-1 · DOI
- Lopez-Serna, 2012, Treatment of craniopharyngioma in adults: systematic analysis of a 25-year experience, Arch Med Res., 43, 347, 10.1016/j.arcmed.2012.06.009 · DOI
- Hetelekidis, 1993, 20-year experience in childhood craniopharyngioma, Int J Radiat Oncol Biol Phys., 27, 189, 10.1016/0360-3016(93)90227-M · DOI · Paper page
- Chakrabarti, 2005, Long-term neurological, visual, and endocrine outcomes following transnasal resection of craniopharyngioma, J Neurosurg., 102, 650, 10.3171/jns.2005.102.4.0650 · DOI · Paper page
- Conti, 2019, Benefits of image-guided stereotactic hypofractionated radiation therapy as adjuvant treatment of craniopharyngiomas. A review, Childs Nerv Syst., 35, 53, 10.1007/s00381-018-3954-z · DOI
- Chemaitilly, 2015, Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study, J Clin Oncol., 33, 492, 10.1200/JCO.2014.56.7933 · DOI · Paper page
- Kawamata, 2010, Optimal treatment strategy for craniopharyngiomas based on long-term functional outcomes of recent and past treatment modalities, Neurosurg Rev., 33, 71, 10.1007/s10143-009-0220-6 · DOI
- Xu, 2020, Cranial irradiation alters neuroinflammation and neural proliferation in the pituitary gland and induces late-onset hormone deficiency, J Cell Mol Med., 24, 14571, 10.1111/jcmm.16086 · DOI
- Nie, 2017, The purine receptor P2X7R regulates the release of pro-inflammatory cytokines in human craniopharyngioma, Endocr Relat Cancer., 24, 287, 10.1530/ERC-16-0338 · DOI
- Zhou, 2017, Interleukin6 induces an epithelialmesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration, Mol Med Rep., 15, 4123, 10.3892/mmr.2017.6538 · DOI
- Neuhaus, 2017, Catecholamine metabolism induces mitochondrial DNA deletions and leads to severe adrenal degeneration during aging, Neuroendocrinology., 104, 72, 10.1159/000444680 · DOI
- Mao, 2019, Interleukin-1alpha leads to growth hormone deficiency in adamantinomatous craniopharyngioma by targeting pericytes: implication in pituitary fibrosis, Metabolism., 101, 153998, 10.1016/j.metabol.2019.153998 · DOI
- Cook, 2009, American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients-−2009 update, Endocr Pract., 2009, 1, 10.4158/EP.15.S2.1 · DOI · Paper page
- Fenske, 2012, Clinical review: current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review, J Clin Endocrinol Metab., 97, 3426, 10.1210/jc.2012-1981 · DOI · Paper page
- Qi, 2013, Growth and weight of children with craniopharyngiomas based on the tumour location and growth pattern, J Clin Neurosci., 20, 1702, 10.1016/j.jocn.2012.12.030 · DOI
- Tan, 2017, The neuroendocrine sequelae of paediatric craniopharyngioma: a 40-year meta-data analysis of 185 cases from three UK centres, Eur J Endocrinol., 176, 359, 10.1530/EJE-16-0812 · DOI
- Sun, 2017, Factors related to endocrine changes and hormone substitution treatment during pre- and post-operation stages in craniopharyngioma, Oncol Lett., 13, 250, 10.3892/ol.2016.5418 · doi:10.3892/ol.2016.5418
- Boekhoff, 2019, Craniopharyngiomas presenting as incidentalomas: results of KRANIOPHARYNGEOM 2007, Pituitary., 22, 532, 10.1007/s11102-019-00983-7 · DOI
- Siebert, 2018, The use and abuse of human growth hormone in sports, Sports Health., 10, 419, 10.1177/1941738118782688 · DOI
- Losa, 2020, Growth hormone therapy does not increase the risk of craniopharyngioma and nonfunctioning pituitary adenoma recurrence, J Clin Endocrinol Metab, 105, dgaa089, 10.1210/clinem/dgaa089 · DOI
- Tiulpakov, 1998, Growth in children with craniopharyngioma following surgery, Clin Endocrinol., 49, 733, 10.1046/j.1365-2265.1998.00590.x · DOI
- Xu, 2017, features of growth hormone deficiency in children with short stature caused by pituitary lesions, Exp Ther Med., 13, 3474, 10.3892/etm.2017.4377 · DOI
- Alotaibi, 2018, Physiologic growth hormone-replacement therapy and craniopharyngioma recurrence in pediatric patients: a meta-analysis, World Neurosurg., 109, 487, 10.1016/j.wneu.2017.09.164 · DOI
- Smith, 2016, Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study, J Neurosurg Pediatr., 18, 408, 10.3171/2016.4.PEDS16112 · DOI
- Boekhoff, 2018, Long-term effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: results of the german craniopharyngioma registry (HIT-Endo), Eur J Endocrinol., 179, 331, 10.1530/EJE-18-0505 · DOI · Paper page
- Monson, 2003, Long-term experience with GH replacement therapy: efficacy and safety, Eur J Endocrinol, 2003, S9, 10.1530/eje.0.148s009 · DOI
- Yuen, 2018, Relative risks of contributing factors to morbidity and mortality in adults with craniopharyngioma on growth hormone replacement, J Clin Endocrinol Metab., 103, 768, 10.1210/jc.2017-01542 · DOI
- Ogawa, 2015, Prognostic factors of craniopharyngioma with special reference to autocrine/paracrine signaling: underestimated implication of growth hormone receptor, Acta Neurochir., 157, 1731, 10.1007/s00701-015-2519-0 · DOI
- Matovic, 2019, Adrenocorticotropic hormone (ACTH) and cortisol monitoring as stress markers during laparoscopic cholecystectomy: standard and low intraabdominal pressure and open cholecystectomy, Med Arch., 73, 257, 10.5455/medarh.2019.73.257-261 · DOI
- Rose, 2005, ACTH deficiency in childhood cancer survivors, Pediatr Blood Cancer., 45, 808, 10.1002/pbc.20327 · DOI
- Thompson, 2019, Management of hypothalamic disease in patients with craniopharyngioma, Clin Endocrinol (Oxf)., 90, 506, 10.1111/cen.13929 · DOI
- Garrè, 2007, Craniopharyngioma: modern concepts in pathogenesis and treatment, Curr Opin Pediatr., 19, 471, 10.1097/MOP.0b013e3282495a22 · DOI · Paper page
- Sherlock, 2009, ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly, J Clin Endocrinol Metab., 94, 4216, 10.1210/jc.2009-1097 · DOI · Paper page
- Okinaga, 2005, High risk of osteopenia and bone derangement in postsurgical patients with craniopharyngiomas, pituitary adenomas and other parasellar lesions, Endocr J., 52, 751, 10.1507/endocrj.52.751 · DOI
- Alvarez, 2006, Craniopharyngiomas, J Neurosci Nurs., 38, 362, 10.1097/01376517-200610000-00007 · doi:10.1097/01376517-200610000-00007
- Pereira, 2005, High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma, Clin Endocrinol., 62, 197, 10.1111/j.1365-2265.2004.02196.x · DOI · Paper page
- Tomlinson, 2001, Association between premature mortality and hypopituitarism, Lancet., 357, 425, 10.1016/S0140-6736(00)04006-X · DOI · Paper page
- Emmert, 2021, Case report of transgender patient with gonadotropic dysfunction secondary to craniopharyngioma: toward improving understanding of biopsychosocial dynamics of gender identity in neurosurgical care, World Neurosurg., 145, 448, 10.1016/j.wneu.2020.09.168 · DOI
- Holmer, 2011, Hypothalamic involvement and insufficient sex steroid supplementation are associated with low bone mineral density in women with childhood onset craniopharyngioma, Eur J Endocrinol., 165, 25, 10.1530/EJE-11-0229 · DOI
- Du, 2014, Hypopituitarism and successful pregnancy, Int J Clin Exp Med., 7, 4660
- Sowithayasakul, 2021, Pregnancies after childhood craniopharyngioma: results of Kraniopharyngeom 2000/2007 and review of the literature, Neuroendocrinology., 111, 16, 10.1159/000506639 · DOI
- Halac, 2005, Endocrine manifestations of craniopharyngioma, Childs Nerv Syst., 21, 640, 10.1007/s00381-005-1246-x · DOI
- Aversa, 2016, Key-role of thyrotropin deficiency in disclosing craniopharyngioma diagnosis in a short girl with Hashimoto's thyroiditis, Minerva Pediatr., 68, 152
- Cook, 2016, Parent observed neuro-behavioral and pro-social improvements with oxytocin following surgical resection of craniopharyngioma, J Pediatr Endocrinol Metab., 29, 995, 10.1515/jpem-2015-0445 · DOI
- Romano, 2015, from autism to eating disorders and more: the role of oxytocin in neuropsychiatric disorders, Front Neurosci., 9, 497, 10.3389/fnins.2015.00497 · DOI
- Marazziti, 2008, Catena Dell'osso M. The role of oxytocin in neuropsychiatric disorders, Curr Med Chem., 15, 698, 10.2174/092986708783885291 · DOI
- Daughters, 2017, Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability, Endocrine., 57, 166, 10.1007/s12020-017-1332-3 · DOI
- Gebert, 2018, De-masking oxytocin-deficiency in craniopharyngioma and assessing its link with affective function, Psychoneuroendocrinology., 88, 61, 10.1016/j.psyneuen.2017.11.006 · DOI
- Daubenbuchel, 2019, Eating behaviour and oxytocin in patients with childhood-onset craniopharyngioma and different grades of hypothalamic involvement, Pediatr Obes., 14, e12527, 10.1111/ijpo.12527 · DOI · Paper page
- Daubenbuchel, 2016, Oxytocin in survivors of childhood-onset craniopharyngioma, Endocrine., 54, 524, 10.1007/s12020-016-1084-5 · DOI · Paper page
- Thompson, 1986, The osmotic thresholds for thirst and vasopressin release are similar in healthy man, Clin Sci, 71, 651, 10.1042/cs0710651 · DOI · Paper page
- Harrois, 2019, Diabetes insipidus and syndrome of inappropriate antidiuretic hormone in critically ill patients, Crit Care Clin., 35, 187, 10.1016/j.ccc.2018.11.001 · DOI
- Pratheesh, 2013, Incidence, predictors and early post-operative course of diabetes insipidus in paediatric craniopharygioma: a comparison with adults, Childs Nerv Syst., 29, 941, 10.1007/s00381-013-2041-8 · DOI
- Lindner, 2013, Hypernatremia in critically ill patients, J Critic Care, 28, 216.e11, 10.1016/j.jcrc.2012.05.001 · DOI · Paper page
- Xiong, 2016, [Influence of preventive use of vasopressin tannate on diabetes insipidus and serum sodium at the early postoperation of craniopharyngioma], J Central South Univ Med Sci., 41, 1058, 10.11817/j.issn.1672-7347.2016.10.008 · doi:10.11817/j.issn.1672-7347.2016.10.008
- Karavitaki, 2014, Management of craniopharyngiomas, J Endocrinol Invest., 37, 219, 10.1007/s40618-013-0050-9 · DOI
- Venegas, 2015, en representacion del area de conocimiento de Neuroendocrinologia de la S. (Practice guideline for diagnosis and treatment of craniopharyngioma and parasellar tumors of the pituitary gland), Endocrinol Nutr, 62, e1, 10.1016/j.endonu.2014.05.005 · DOI
- Winkfield, 2011, Long-term clinical outcomes following treatment of childhood craniopharyngioma, Pediatr Blood Cancer., 56, 1120, 10.1002/pbc.22884 · doi:10.1002/pbc.22884
- Loh, 2008, Disorders of water and salt metabolism associated with pituitary disease, Endocrinol Metab Clin North Am, 37, 213, 10.1016/j.ecl.2007.10.008 · DOI
- Cote, 2020, Optimizing pre-, intra-, and postoperative management of patients with sellar pathology undergoing transsphenoidal surgery, Neurosurg Focus., 48, E2, 10.3171/2020.3.FOCUS2043 · DOI
- Seay, 2020, Diagnosis and management of disorders of body tonicity-hyponatremia and hypernatremia: core curriculum 2020, Am J Kidney Dis., 75, 272, 10.1053/j.ajkd.2019.07.014 · doi:10.1053/j.ajkd.2019.07.014
- Refardt, 2020, Diabetes insipidus: an update, Endocrinol Metab Clin North Am., 49, 517, 10.1016/j.ecl.2020.05.012 · DOI
- Mutter, 2021, Diabetes insipidus: pathogenesis, diagnosis, and clinical management, Cureus., 13, e13523, 10.7759/cureus.13523 · DOI
- Vance, 2004, Treatment of patients with a pituitary adenoma: one clinician's experience, Neurosurg Focus., 16, E1, 10.3171/foc.2004.16.4.2 · doi:10.3171/foc.2004.16.4.2
- Hensen, 1999, Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas, Clin Endocrinol., 50, 431, 10.1046/j.1365-2265.1999.00666.x · DOI · Paper page
- Dumont, 2005, Postoperative care following pituitary surgery, J Intensive Care Med., 20, 127, 10.1177/0885066605275247 · DOI
- Oksnes, 2015, Optimal glucocorticoid replacement in adrenal insufficiency, Best Pract Res Clin Endocrinol Metab., 29, 3, 10.1016/j.beem.2014.09.009 · DOI
- Falorni, 2013, Therapy of adrenal insufficiency: an update, Endocrine., 43, 514, 10.1007/s12020-012-9835-4 · DOI
- Zeni, 2019, Evaluation of treatment of central hypothyroidism versus primary hypothyroidism in relation to levothyroxine replacement dose, Endocr Pract., 25, 663, 10.4158/EP-2018-0533 · DOI
- Parretti, 2016, Current recommendations in the management of hypothyroidism: developed from a statement by the British Thyroid Association Executive, Br J Gen Pract., 66, 538, 10.3399/bjgp16X687493 · DOI
- Aimaretti, 2015, Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA, J Endocrinol Invest., 38, 377, 10.1007/s40618-014-0201-7 · DOI · Paper page
- Losa, 2008, Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency, Thyroid., 18, 1249, 10.1089/thy.2008.0266 · DOI · Paper page
- Yao, 2021, The effects of recombinant human growth hormone therapy on thyroid function in pediatric patients with growth hormone deficiency, Transl Pediatr., 10, 851, 10.21037/tp-20-401 · DOI
- Çakir, 2015, Retrospective evaluation of pubertal development and linear growth of girls with Turner Syndrome treated with oral and transdermal estrogen, J Pediatr Endocrinol Metab., 28, 1219, 10.1515/jpem-2014-0007 · DOI
- Backeljauw, 2019, Sex hormone replacement therapy for individuals with Turner syndrome, Am J Med Genet C Semin Med Genet., 181, 13, 10.1002/ajmg.c.31685 · DOI
- Ascoli, 2006, Hypopituitarism, Pituitary., 9, 335, 10.1007/s11102-006-0416-5 · DOI
- Conway, 2000, Premature ovarian failure, Br Med Bull., 56, 643, 10.1258/0007142001903445 · DOI
- Alexandraki, 2019, Management of hypopituitarism, J Clin Med, 8, 2153, 10.3390/jcm8122153 · DOI
- Levy, 2019, Diabetes insipidus, BMJ., 364, l321, 10.1136/bmj.l321 · DOI
- Woodmansee, 2015, American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Postoperative Management Following Pituitary Surgery, Endocr Pract., 21, 832, 10.4158/EP14541.DSCR · DOI
- Sadashivam, 2020, Adult craniopharyngioma: The role of extent of resection in tumor recurrence and long-term functional outcome, Clin Neurol Neurosurg., 192, 105711, 10.1016/j.clineuro.2020.105711 · DOI
- Gump, 2015, Identification of targets for rational pharmacological therapy in childhood craniopharyngioma, Acta Neuropathol Commun., 3, 30, 10.1186/s40478-015-0211-5 · DOI
- Brastianos, 2014, Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas, Nat Genet., 46, 161, 10.1038/ng.2868 · DOI · Paper page
- Ascierto, 2013, Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma, J Clin Oncol., 31, 3205, 10.1200/JCO.2013.49.8691 · DOI · Paper page
- Hengartner, 2020, Adamantinomatous craniopharyngioma: moving toward targeted therapies, Neurosurg Focus., 48, E7, 10.3171/2019.10.FOCUS19705 · DOI
- Brastianos, 2016, Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy, J Natl Cancer Inst., 108, djv310, 10.1093/jnci/djv310 · DOI · Paper page
- Grob, 2019, Targeting IL-6 Is a potential treatment for primary cystic craniopharyngioma, Front Oncol., 9, 791, 10.3389/fonc.2019.00791 · DOI
Cited by
van Santen, H. M., & Müller, H. L. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf025 · Cited by 21
Marshall, E., Joshi, N., Crowley, J., McCormack, S., Cheng, S., Faig, W., Storm, P. B., Resnick, A., Mueller, S., Malbari, F., et al. (2023) · Neoplasia · doi:10.1016/j.neo.2022.100873 · Cited by 4
Metadata
- Authors
- Zhou, Z., Zhang, S., & Hu, F.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2021-12-02
- Volume
- 12
- ISSN
- 1664-2295
- Cited by
- 48
- References
- 23
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endocrine Disorder in Patients With Craniopharyngioma. https://app.cochat.ai/papers/10.3389/fneur.2021.737743
- The paper
- Zhou, Z., Zhang, S., & Hu, F. (2021). Endocrine Disorder in Patients With Craniopharyngioma. Frontiers in Neurology. https://doi.org/10.3389/fneur.2021.737743
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.